|Asset Group||Asset Sub-Group||Investment Category|
WHY WE RECOMMEND IT
Experienced management group: Gravis Capital specialises in long-term infrastructure, property and asset-backed investments. Will Argent, the fund’s adviser, has managed this fund since its inception in December 2017.
Focus on clean energy and attractive income: The fund offers exposure to companies engaged in the provision, storage, supply and consumption of clean energy. The fund’s trailing 12 month net yield was 3.59% as at 30 April 2020.
It is reasonably priced: This specialist investment trust levies annual ongoing charges of 0.80% as at 31 December 2019.
ii ACE ethical style: Embraces. This means the investment trust adopts a targeted or proactive approach to ethical investing, in an effort to make a positive impact and/or environmental outcomes.
Fund EcoMarket category: Environmentally Themed. This applies to funds that significantly integrate environmental issues into their investment strategies, sometimes alongside ethical avoidance criteria. Their focus is often around longer term environmental and resource related issues.
How the fund is managed: The fund invests in a diversified portfolio of global listed securities of companies involved in the operation, funding, construction, generation and supply of clean energy. It aims to deliver a regular income expected to be 4.5% per annum after charges (this is an unofficial target) and aims to preserve investors’ capital throughout market cycles.
Environmental focus: In certain market conditions the performance of the fund may differ significantly from others in the peer group that do not exclude specific sectors or companies from a comparable investment universe.
Portfolio concentration: The fund has a highly focused portfolio. As at 30 April 2020 the top 10 stocks represented 56.5% of assets under management.
Currency: Because almost half of the fund’s investments are not quoted in sterling, performance may be affected by changes in exchange rates.
Fund size: The fund is comparatively small, with £73.86 million under management as at 30 April 2020.
|Information and data compiled to 30 April 2020.|
The information we provide in the ACE 30 investments list does not constitute a "personal recommendation". You should ensure that any investment decisions you make are suitable for your personal circumstances and that the ethical style of the investment reflects your personal beliefs.
Past performance of the underlying constituents is not a guarantee of future performance. Remember, the value of investments, and any income from them, can fall as well as rise so you could get back less than you invest.
Annual performance can be found on the factsheet of each fund, trust or ETF. Simply click on the asset’s name and then the performance tab.
If you are unsure about the suitability of a particular investment or think that you need a personal recommendation, you should speak to a suitably qualified financial advisor.
Any changes to the ii ACE 30 investments list and the rationale behind those decisions will be communicated through the Quarterly Investment Outlook.
Details of all recommendations issued by ii during the previous 12 month period can be found here.
ii adheres to a strict code of conduct. Members of ii staff may hold shares in companies mentioned in the ii ACE 30 investments list, which could create a conflict of interest. Any member of staff intending to complete some research about any financial instrument in which they have an interest are required to disclose such interest to ii. We will at all times consider whether such interest impairs the objectivity of the recommendation.
In addition, staff involved in the production of this ii ACE 30 list are subject to a personal account dealing restriction. This prevents them from placing a transaction in the specified instrument(s) for five working days before and after an investment is included or amended and made public within the list. This is to avoid personal interests conflicting with the interests of the recipients of this ii ACE 30 investments list.